Spyre Therapeutics (SYRE) Receivables - Other (2015 - 2023)

Spyre Therapeutics (SYRE) has 3 years of Receivables - Other data on file, last reported at $163000.0 in Q3 2023.

• Quarterly Receivables - Other fell 75.64% year-over-year to $163000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $163000.0 (down 75.64% YoY) and the FY2022 annual result came in at $375000.0, down 53.99% from the prior year.
• Receivables - Other eased to $163000.0 in Q3 2023, from $1.6 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.6 million in Q2 2023 to a low of $163000.0 in Q3 2023.
• A 3-year average of $686125.0 and a median of $574000.0 in 2022 frame the typical range for Receivables - Other.
• The widest YoY moves for Receivables - Other: up 243.63% in 2023, down 75.64% in 2023.
• Tracing SYRE's Receivables - Other over 3 years: stood at $815000.0 in 2021, then tumbled by 53.99% to $375000.0 in 2022, then tumbled by 56.53% to $163000.0 in 2023.
• The last three Receivables - Other figures came in at $163000.0 (Q3 2023), $1.6 million (Q2 2023), and $330000.0 (Q1 2023), per Business Quant data.